Results 51 to 60 of about 15,278 (270)

Is there NO treatment for severe sepsis? [PDF]

, 2008
Sepsis is a systemic inflammatory response syndrome in the presence of suspected or proven infection, and it may progress to or encompass organ failure (severe sepsis) and hypotension (septic shock).
Bredan, Amin, Cauwels, Anje
core   +2 more sources

Hypercontractile esophagus responsive to potassium-competitive acid blockers: a case report

BMC Gastroenterology, 2022
Abstract Background Hypercontractile esophagus is a rare hypercontractile esophageal motility disorder. The etiology of hypercontractile esophagus is unknown but an association between acid reflux and hypercontractile esophagus has been suggested.
Yuyang Shao, Chen Xie, Huang Feng, Donglin Yan, Weichang Chen   +4 more
openaire   +3 more sources

Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis

Gut and Liver, 2023
Background/Aims: Fexuprazan is a novel potassium-competitive acid blocker that could be of benefit to patients with gastric mucosal injury. The aim of this study was to assess the 2-week efficacy and safety of fexuprazan in patients with acute or chronic
Gwang Ha Kim, Myung-Gyu Choi, Jin Il Kim, Soo Teik Lee, Hoon Jai Chun, Kook Lae Lee, Suk Chei Choi, Jae-Young Jang, Yong Chan Lee, Jae Gyu Kim, Ki Bae Kim, Ki-Nam Shim, Chong Il Sohn, Sung Kook Kim, Sang Gyun Kim, Jin Seok Jang, Nayoung Kim, Hwoon-Yong Jung, Hyojin Park, Kyu Chan Huh, Kwang Jae Lee, Su Jin Hong, Song Baek, Jin Joo Han, Oh Young Lee   +24 more
doaj   +1 more source

Overview of Antagonists Used for Determining the Mechanisms of Action Employed by Potential Vasodilators with Their Suggested Signaling Pathways [PDF]

, 2016
This paper is a review on the types of antagonists and the signaling mechanism pathways that have been used to determine the mechanisms of action employed for vasodilation by test compounds.
Ahmad, Mariam, Asmawi, Mohd Zaini, Chu, Shan Tan, Mun, Fei Yam, Yean, Chun Loh, Yung, Sing Ch’ng   +5 more
core   +1 more source

The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy

Pharmaceuticals, 2020
Helicobacter pylori infection is a severe global health problem that is closely associated with acid-related diseases and gastric malignancies. Eradicating H.
Muhammad Miftahussurur, Boby Pratama Putra, Yoshio Yamaoka   +2 more
doaj   +1 more source

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects

Pharmaceutics, 2023
Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive acid blocker, fexuprazan is expected to prevent aspirin-induced gastrointestinal ...
JungJin Oh, Eunsol Yang, In-Jin Jang, Hyejung Lee, Hokyun Yoo, Jae-Yong Chung, SeungHwan Lee, Jaeseong Oh   +7 more
doaj   +1 more source

Inactivation of anandamide signaling : A continuing Debate [PDF]

, 2010
Copyright 2011 Elsevier B.V., All rights reserved.Peer reviewedPublisher ...
Ahluwalia, Ahn, Alexander, Alexander, Beltramo, Bhave, Bifulco, Bisogno, Bisogno, Bosier, Cadas, Chen, Chuang, Clapper, Cravatt, Cravatt, Cristino, Day, De Petrocellis, De Petrocellis, De Petrocellis, Desarnaud, Deutsch, Deutsch, Devane, Devane, Di Carlo, Di Marzo, Di Marzo, Di Marzo, Egertova, Evans, Evans, Evans, Fedorova, Glaser, Guzmán, Hampson, Hanus, Harizi, Hesham Khairy, Hillard, Hillard, Hillard, Horvath, Howlett, Howlett, Iversen, Jarrahian, Jiang, Jonsson, Kaczocha, Kaczocha, Katayama, Kathuria, Khairy, Klein, Koutek, Kulkarni-Narla, Liu, Long, Maccarrone, Malcher-Lopes, Matsuda, McFarland, Mechoulam, Mechoulam, Mechoulam, Mechoulam, Miller, Moore, Mulder, Munro, Numazaki, Okamoto, Ortar, Pertwee, Piomelli, Poling, Porter, Premkumar, Randall, Schlosburg, Schmid, Simon, Stella, Stremmel, Sun, Sun, Sánchez, Thomas, Thors, Tian, Tsou, Tsuboi, Ueda, Ueda, Van den Bossche, Van Der Stelt, Wael E. Houssen, Walker, Weber, Wenger, Wood, Woodward, Yu, Zygmunt   +106 more
core   +3 more sources

Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases

Pharmacology & Therapeutics, 2016
Acid-related diseases (ARDs), such as peptic ulcers and gastroesophageal reflux disease, represent a major health-care concern. Some major milestones in our understanding of gastric acid secretion and ARD treatment reached during the last 50years include 1) discovery of histamine H2-receptors and development of H2-receptor antagonists, 2 ...
Inatomi, Nobuhiro, Matsukawa, Jun, Sakurai, Yuuichi, Otake, Kazuyoshi   +3 more
openaire   +2 more sources

Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers

Current Treatment Options in Gastroenterology, 2021
AbstractPurpose of the reviewThe introduction of H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) into clinical practice has been a real breakthrough in the treatment of acid-related diseases. PPIs are now the standard of care for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD),Helicobacter ...
Carmelo Scarpignato, Richard H. Hunt
openaire   +1 more source

Lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan

JGH Open, 2021
Background and Aim The aim of the present study was to examine the lifestyle‐ and comorbidity‐related determinant factors of the prescription of proton pump inhibitors (PPIs) for patients in whom Helicobacter pylori has been eradicated, and to evaluate ...
Furitsu Shimada, Hiroyoshi Endo, Ayako Takamori, Takuya Matsunaga, Shun Fujimoto, Shimpei Shirai, Toshihiko Kakiuchi, Takashi Akutagawa, Yasuhisa Sakata, Koichi Node, Kohei Yamanouchi, Shotaro Nakamura, Kazuma Fujimoto, Motohiro Esaki   +13 more
doaj   +1 more source